Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
01 2020
Historique:
received: 19 06 2019
revised: 07 08 2019
accepted: 23 08 2019
pubmed: 8 9 2019
medline: 22 1 2021
entrez: 8 9 2019
Statut: ppublish

Résumé

Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated the ability of a comprehensive geriatric assessment (CGA) to predict post-alloHCT outcomes in a single-center prospective cohort study of patients age 50 years and older. Outcomes included overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM). A total of 148 patients were included, with a median age of 62 years (range, 50 to 76 years). In multivariate regression analysis, several CGA measures of functional status were predictive of post-alloHCT outcomes, after adjusting for traditional prognostic factors. Any deficit in instrumental activities of daily living (IADL) was associated with inferior OS (hazard ratio [HR], 1.81, 95% confidence interval [CI], 1.07 to 3.08; P = .03) and PFS (HR, 1.85; 95% CI, 1.15 to 2.99; P = .01). A Medical Outcomes Study Physical Health scale (MOS-PH) score <85 was associated with inferior OS (HR, 1.96; 95% CI, 1.13 to 3.40; P = .02), PFS (HR, 1.75; 95% CI, 1.07 to 2.88; P = .03), and increased NRM (subdistribution HR, 2.57; 95% CI, 1.12 to 5.92; P = .03). MOS-PH score was also associated with the number of non-hematologic grade ≥3 adverse events within the first 100 days after alloHCT (rate ratio, 1.61; 95% CI, 1.04 to 2.49; P = .03). These findings support previous work suggesting that IADL is an important prognostic tool prior to alloHCT. MOS-PH is newly identified as an additional metric to identify older patients at higher risk of poor post-alloHCT outcomes, including toxicity and NRM.

Identifiants

pubmed: 31493541
pii: S1083-8791(19)30562-2
doi: 10.1016/j.bbmt.2019.08.022
pmc: PMC6942208
mid: NIHMS1539169
pii:
doi:

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

189-196

Subventions

Organisme : NIA NIH HHS
ID : K24 AG049057
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG044281
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG000212
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

J Clin Oncol. 1994 Mar;12(3):601-7
pubmed: 8120560
Bone Marrow Transplant. 2018 May;53(5):565-575
pubmed: 29330399
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
Biol Blood Marrow Transplant. 2017 Jan;23(1):44-52
pubmed: 27720995
BMC Psychiatry. 2008 Feb 19;8:10
pubmed: 18284689
J Clin Oncol. 2010 Jan 20;28(3):405-11
pubmed: 20008642
Oncology (Williston Park). 2001 Dec;15(12):1567-77, 1580; discussion 1581, 1586, 1591
pubmed: 11780701
Blood. 2019 Jul 25;134(4):374-382
pubmed: 31167800
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
J Clin Oncol. 2010 Apr 10;28(11):1878-87
pubmed: 20212255
JAMA. 2011 Nov 2;306(17):1874-83
pubmed: 22045765
J Gerontol. 1981 Jul;36(4):428-34
pubmed: 7252074
Soc Sci Med. 1991;32(6):705-14
pubmed: 2035047
Blood. 2013 May 23;121(21):4287-94
pubmed: 23550038
Bone Marrow Transplant. 1997 Feb;19(4):357-68
pubmed: 9051246
Bone Marrow Transplant. 2013 Sep;48(9):1253-6
pubmed: 23503530
Biol Blood Marrow Transplant. 2013 Mar;19(3):429-34
pubmed: 23160006
Cancer. 2005 Nov 1;104(9):1998-2005
pubmed: 16206252
Cancer. 2017 Dec 1;123(23):4687-4700
pubmed: 28817182
Bone Marrow Transplant. 2018 Sep;53(9):1184-1187
pubmed: 29523890
Blood. 2017 Aug 31;130(9):1156-1164
pubmed: 28674027
J Clin Oncol. 2011 Apr 1;29(10):1290-6
pubmed: 21357782
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
Cancer. 2016 Jan 1;122(1):91-8
pubmed: 26439325
J Geriatr Oncol. 2014 Oct 1;5(4):422-30
pubmed: 24835889
J Clin Oncol. 2015 Dec 10;33(35):4167-75
pubmed: 26527780
Haematologica. 2014 Aug;99(8):1373-9
pubmed: 24816237
J Am Geriatr Soc. 1999 Sep;47(9):1072-6
pubmed: 10484248
Am J Psychiatry. 1983 Jun;140(6):734-9
pubmed: 6846631
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685

Auteurs

Li-Wen Huang (LW)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Ying Sheng (Y)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

Charalambos Andreadis (C)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Aaron C Logan (AC)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Gabriel N Mannis (GN)

Division of Hematology, Department of Medicine, Stanford University, Stanford, California.

Catherine C Smith (CC)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Karin M L Gaensler (KML)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Thomas G Martin (TG)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Lloyd E Damon (LE)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California.

Michael A Steinman (MA)

Division of Geriatrics, Department of Medicine, University of California San Francisco, and the San Francisco VA Medical Center, San Francisco, California.

Chiung-Yu Huang (CY)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

Rebecca L Olin (RL)

Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. Electronic address: rebecca.olin@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH